Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

. 2023 Jan ; 37 (1) : 222-225. [epub] 20221208

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid36482128
E-zdroje Online Plný text
Odkazy

PubMed 36482128
PubMed Central PMC9883152
DOI 10.1038/s41375-022-01770-3
PII: 10.1038/s41375-022-01770-3
Knihovny.cz E-zdroje

Zobrazit více v PubMed

Eckert C, Parker C, Moorman AV, Irving JAE, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175–89. doi: 10.1016/j.ejca.2021.03.034. PubMed DOI

Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807–16. doi: 10.1182/blood-2012-02-265884. PubMed DOI

Salzer WL, Burke MJ, Devidas M, Dai Y, Heerema NA, Carroll AJ, et al. Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131. Abstract from the 2021 American Society of Clinical Oncology Annual Meeting. J Clin Oncol. 2021;39:10004. doi: 10.1200/JCO.2021.39.15_suppl.10004. DOI

Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833–42. doi: 10.1001/jama.2021.0669. PubMed DOI PMC

Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10:77. doi: 10.1038/s41408-020-00342-x. PubMed DOI PMC

Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843–54. doi: 10.1001/jama.2021.0987. PubMed DOI PMC

Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–12. doi: 10.1182/blood-2015-09-670729. PubMed DOI

Klinger M, Zugmaier G, Nägele V, Goebeler M-E, Brandl C, Stelljes M, et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 2020;80:91–101. doi: 10.1158/0008-5472.CAN-19-1131. PubMed DOI

Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, et al. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022;69:e29715. doi: 10.1002/pbc.29715. PubMed DOI

Brown P, Zugmaier G, Gore L, Tuglus CA, von Stackelberg A. Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL. Br J Haematol. 2020;188:e36–9. doi: 10.1111/bjh.16306. PubMed DOI

Mejstrikova E, Klinger M, Markovic A, Zugmaier G, Locatelli F. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. Pediatr Blood Cancer. 2021;68:e29323. doi: 10.1002/pbc.29323. PubMed DOI

Goekbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017;102:e132–5. doi: 10.3324/haematol.2016.153957. PubMed DOI PMC

Jabbour E, Dull J, Yilmaz M, Khoury JD, Ravandi F, Jain N, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol. 2018;93:371–4. doi: 10.1002/ajh.24987. PubMed DOI

Queudeville M, Schlegel P, Heinz AT, Lenz T, Doring M, Holzer U, et al. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Eur J Haematol. 2020;106:473–83. doi: 10.1111/ejh.13569. PubMed DOI

Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T cell therapy. Blood. 2021;138:531–43. doi: 10.1182/blood.2020009515. PubMed DOI PMC

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace